- 全部删除
 
您的购物车当前为空
PFK-015 (PFK15) 是一种有效的 PFKFB3 抑制剂,对重组PFKFB3的IC50为110 nM。它能抑制 Y 细胞中的 PFKFB3 活性,IC50为20 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
PFK-015 (PFK15) 是一种有效的 PFKFB3 抑制剂,对重组PFKFB3的IC50为110 nM。它能抑制 Y 细胞中的 PFKFB3 活性,IC50为20 nM。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 1 mg | ¥ 197  | In stock | |
| 5 mg | ¥ 452  | In stock | |
| 10 mg | ¥ 651  | In stock | |
| 25 mg | ¥ 1,250  | In stock | |
| 50 mg | ¥ 2,250  | In stock | |
| 100 mg | ¥ 3,380  | In stock | |
| 200 mg | ¥ 4,690  | In stock | |
| 500 mg | ¥ 7,220  | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 489  | In stock | 
PFK-015 相关产品
| 产品描述 | PFK-015 (PFK15) is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).  | 
| 靶点活性 |  PFKFB3:110 nM, PFKFB3:20 nM  | 
| 体外活性 | PFK-015(25 mg/kg,i.p.)对同源小鼠体内LLC肿瘤的生长、转移扩散及葡萄糖代谢具有抑制作用.在三个人异种移植的无胸腺癌症小鼠模型中,PFK-015与公认化疗药物的抗癌效果相似.PFK-015有适当的体内药代动力学性质.  | 
| 体内活性 | 在Jurkat T-细胞白血病细胞和H522肺腺癌细胞中,PFK-015可使F26BP、葡萄糖摄取及细胞内腺嘌呤核苷三磷酸水平降低。PFK-015还对一系列癌细胞的生长具有明显的抑制作用。  | 
| 激酶实验 | Recombinant PFKFB3 assay: Kinase reactions are conducted by incubating 13 ng of recombinant human PFKFB3 protein in a reaction mix containing 10 μmol/L ATP, 10 μmol/L F6P, and either dimethyl sulfoxide (DMSO) vehicle control, 3PO, or PFK15 for 1 hour at room temperature. Kinase activity is measured with the Adapta Universal Kinase Assay per manufacturer  | 
| 细胞实验 | Viability is determined using trypan blue exclusion. Cells were incubated in 20% trypan blue for 5 minutes. Cells excluding trypan blue are counted using a standard hemocytometer to determine the total number of viable cells. Experiments are conducted in triplicate. (Only for Reference)  | 
| 别名 | PFK15, PFK 015 | 
| 分子量 | 260.29 | 
| 分子式 | C17H12N2O | 
| CAS No. | 4382-63-2 | 
| Smiles | O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1 | 
| 密度 | 1.237 g/cm3 (Predicted) | 
| 颜色 | White | 
| 物理性状 | Solid | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| 溶解度信息 | DMSO: 3 mg/mL (11.53 mM), Sonication is recommended.   | ||||||||||||||||||||
溶液配制表  | |||||||||||||||||||||
DMSO 
  | |||||||||||||||||||||
评论内容